Antileishmanial Assessment of Isoxazole Derivatives Against

Overview

Journal RSC Med Chem

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2021 Jan 22

PMID 33479698

Citations 3

Authors

Sushobhan Mukhopadhyay

Dinesh S Barak

R Karthik

Sarvesh K Verma

Rabi S Bhatta

Neena Goyal

Sanjay Batra

Affiliations

Soon will be listed here.

Abstract

A chemical library comprising substituted 3-nitroisoxazoles and 3-aminoisoxazoles was prepared and screened for their antileishmanial activity against . As compared to Miltefosine, the standard drug used in bioassays, several compounds displayed remarkably better inhibition of the promastigote and amastigote stages of parasites. The evaluation of a few compounds in a golden hamster model showed significant reduction of the parasite load post treatment the intraperitoneal route by several compounds. The preliminary pharmacokinetic evaluation of a representative compound the oral route, however, indicated high systemic clearance from the body.

Citing Articles

Integrating traditional QSAR and read-across-based regression models for predicting potential anti-leishmanial azole compounds.

Nandi R, Sharma A, Priya A, Kumar D Mol Divers. 2024; .

PMID: 39653961 DOI: 10.1007/s11030-024-11070-w.

Synthesis of Nitrostyrylthiazolidine-2,4-dione Derivatives Displaying Antileishmanial Potential.

Khoumeri O, Hutter S, Primas N, Castera-Ducros C, Carvalho S, Wyllie S Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065730 PMC: 11280390. DOI: 10.3390/ph17070878.

Synthesis and Antiprotozoal Profile of 3,4,5-Trisubstituted Isoxazoles.

Rosa F, Mendes de Souza Melo S, Pianoski K, Poletto J, Dos Santos M, Vieira da Silva M ChemistryOpen. 2021; 10(10):931-938.

PMID: 34331350 PMC: 8485799. DOI: 10.1002/open.202100141.

References

Antinarelli L, Dias R, Souza I, Lima W, Gameiro J, da Silva A . 4-Aminoquinoline Derivatives as Potential Antileishmanial Agents. Chem Biol Drug Des. 2015; 86(4):704-14. DOI: 10.1111/cbdd.12540. View

Ashutosh , Gupta S, Ramesh , Sundar S, Goyal N . Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother. 2005; 49(9):3776-83. PMC: 1195392. DOI: 10.1128/AAC.49.9.3776-3783.2005. View

Bhandari V, Kulshrestha A, Deep D, Stark O, Prajapati V, Ramesh V . Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis. 2012; 6(5):e1657. PMC: 3358331. DOI: 10.1371/journal.pntd.0001657. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Obonaga R, Fernandez O, Valderrama L, Rubiano L, Castro M, Barrera M . Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother. 2013; 58(1):144-52. PMC: 3910710. DOI: 10.1128/AAC.01023-13. View

Barmade M, Murumkar P, Sharma M, Yadav M . Medicinal Chemistry Perspective of Fused Isoxazole Derivatives. Curr Top Med Chem. 2016; 16(26):2863-2883. DOI: 10.2174/1568026616666160506145700. View

Bhattacharya S, Sinha P, Sundar S, Thakur C, Jha T, Pandey K . Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis. 2007; 196(4):591-8. DOI: 10.1086/519690. View

Sundar S, Chakravarty J . Antimony toxicity. Int J Environ Res Public Health. 2011; 7(12):4267-77. PMC: 3037053. DOI: 10.3390/ijerph7124267. View

Mishra M, Singh M, Choudhury D, Singh V, Khan A . Amphotericin B for second-line treatment of Indian kala-azar. Lancet. 1991; 337(8746):926. DOI: 10.1016/0140-6736(91)90268-t. View

10.

Zhu J, Mo J, Lin H, Chen Y, Sun H . The recent progress of isoxazole in medicinal chemistry. Bioorg Med Chem. 2018; 26(12):3065-3075. DOI: 10.1016/j.bmc.2018.05.013. View

11.

Thompson A, OConnor P, Marshall A, Yardley V, Maes L, Gupta S . 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. J Med Chem. 2017; 60(10):4212-4233. PMC: 7722354. DOI: 10.1021/acs.jmedchem.7b00034. View

12.

Dighe S, Mukhopadhyay S, Kolle S, Kanojiya S, Batra S . Synthesis of 3,4,5-Trisubstituted Isoxazoles from Morita-Baylis-Hillman Acetates by an NaNO2 /I2 -Mediated Domino Reaction. Angew Chem Int Ed Engl. 2015; 54(37):10926-30. DOI: 10.1002/anie.201504529. View

13.

da Rosa R, Moraes M, Zimmermann L, Schenkel E, Steindel M, Campos Bernardes L . Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis. Eur J Med Chem. 2017; 128:25-35. DOI: 10.1016/j.ejmech.2017.01.029. View

14.

Trefzger O, Barbosa N, Scapolatempo R, das Neves A, Ortale M, Carvalho D . Design, synthesis, antileishmanial, and antifungal biological evaluation of novel 3,5-disubstituted isoxazole compounds based on 5-nitrofuran scaffolds. Arch Pharm (Weinheim). 2019; 353(2):e1900241. DOI: 10.1002/ardp.201900241. View

15.

Mukherjee T, Roy K, Bhaduri A . Acivicin: a highly active potential chemotherapeutic agent against visceral leishmaniasis. Biochem Biophys Res Commun. 1990; 170(2):426-32. DOI: 10.1016/0006-291x(90)92109-d. View

16.

Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling R . Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol. 2007; 5(11):873-82. DOI: 10.1038/nrmicro1748. View

17.

Patterson S, Fairlamb A . Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Curr Med Chem. 2018; 26(23):4454-4475. DOI: 10.2174/0929867325666180426164352. View

18.

Balasegaram M, Ritmeijer K, Lima M, Burza S, Ortiz Genovese G, Milani B . Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs. 2012; 17(4):493-510. PMC: 3518293. DOI: 10.1517/14728214.2012.748036. View

19.

Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D . Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. J Antimicrob Chemother. 2014; 70(2):518-27. DOI: 10.1093/jac/dku422. View

20.

Pandey K, Pun S, Pandey B . Relapse of kala-azar after use of multiple drugs: a case report and brief review of literature. Indian J Med Microbiol. 2012; 30(2):227-9. DOI: 10.4103/0255-0857.96703. View